CAPITAL4 NEWS

 

  • NIFTY4,860.5  
  • -45.6 -0.9%
  • SENSEX16,026.4  
  • -156.9 -1.0%

Strides Arcolab's subsidiary receives USFDA approval

Source: Capital Market, Thursday, December 15th, 02:58 PM

Strides Arcolab has announced that Onco Therapies, a wholly owned subsidiary of Strides Arcolab (Strides) announced that it has received approvals from USFDA for Cytarabine Injection 20 mg/ mL, packaged in 500 mg/ 25 mL Multiple-dose vials, 20 mg/ mL, packaged in 100 mg/5 mL Single-dose vial and 20 mg/ mL, packaged in 1000 mg/ 50 mL Pharmacy Bulk Packages.

Cytarabine is an anti-cancer chemotherapy drug. Cytarabine is used to treat different forms of leukemia, including acute and chronic myelogenous and acute lymphocytic leukemia. It is also used to treat lymphoma, meningeal leukemia and lymphoma (cancers found in the lining of the brain and spinal cord).

TOP BLOGS

View all blogs